EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

Abstract

Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals’ quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.We call upon Europe’s policy-makers to coordinate actions and improve individual and public health in allergy by:Promoting awareness of the effectiveness of allergen specific immunotherapyUpdating national healthcare policies to support allergen specific immunotherapyPrioritising funding for allergen specific immunotherapy researchMonitoring the macroeconomic and health economic parameters of allergyReinforcing allergy teaching in medical disciplines and specialtiesThe effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.

Does maternal diet during pregnancy and lactation affect outcomes in offspring? A systematic review of food-based approaches

“…Many childhood allergies persist with about 50% of childhood asthma sufferers and 80% of hay fever sufferers continuing to have symptoms into adulthood [6,7]. The cost to the health care system and the burden for the family are high [8,9] and it is estimated that asthma alone costs Europe €25 billion per year [10].…”

Chinese Guideline on allergen immunotherapy for allergic rhinitis

“…Compared to the pharmacological therapies, the inherent benefit of AIT is the potential to treat all clinical expressions of respiratory allergic disease (34). Furthermore, in the long-term AIT can produce economic savings due to a combination of reduced drug usage and improvement of quality of life (35).…”

Impacto de la Inmunoterapia subcutánea con Dermatophagoides farinae y Dermatophagoides pteronyssinus sobre la calidad de vida de pacientes con rinitis y asma alérgica

“…Las conclusiones en este campo muestran la magnitud del problema y la necesidad urgente de soluciones. Cuando se utiliza la inmunoterapia alergénica adecuadamente, después de un diagnóstico cuidadoso y con extractos bien caracterizados y de buena calidad, este tratamiento puede modificar positivamente la vida de las personas que viven con enfermedades alérgicas (12). El presente estudio provee evidencia sobre los cambios en la calidad de vida inducidos por la inmunoterapia subcutánea con D. farinae y D. pteronyssinus en personas con alergia respiratoria.…”